Cyfuse Biomedical K.K.
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/08/01Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥374M | ¥61M | ¥54M | ¥231M |
| Gross Profit | ¥241M | ¥38M | ¥17M | ¥114M |
| Operating Income | -¥425M | -¥697M | -¥896M | -¥828M |
| Pretax Income | -¥444M | -¥576M | -¥860M | -¥747M |
| Net Income | -¥474M | -¥589M | -¥872M | -¥764M |
| EPS | -¥177.67 | -¥75.42 | -¥108.34 | - |
| Operating Margin | -113.52% | -1,141.24% | -1,645.91% | -358.52% |
| Balance Sheet | ||||
| Total Assets | ¥4,815M | ¥4,215M | ¥3,518M | ¥4,266M |
| Total Equity | ¥3,770M | ¥3,203M | ¥2,542M | ¥2,758M |
| Total Liabilities | ¥1,046M | ¥1,011M | ¥976M | ¥1,508M |
| Cash | ¥4,437M | ¥3,874M | ¥3,053M | ¥3,727M |
| Interest-bearing Debt | ¥908M | ¥913M | ¥853M | ¥1,312M |
| Equity Ratio | 78.29% | 76.01% | 72.27% | 64.64% |
| D/E Ratio | 0.24 | 0.29 | 0.34 | 0.48 |
| Cash Flow | ||||
| Operating CF | -¥404M | -¥562M | -¥761M | -¥535M |
| Investing CF | -¥431M | -¥19M | -¥9M | -¥398M |
| Financing CF | ¥2,659M | ¥18M | -¥52M | ¥1,256M |
| Free CF | -¥632M | -¥582M | -¥769M | -¥582M |
| Efficiency | ||||
| ROE | -12.57% | -18.39% | -34.31% | -27.70% |
| ROA | -9.84% | -13.98% | -24.79% | -17.91% |
Latest IR Information
-
2026 Fiscal Year December Interim Earnings Materials
Announcement of the performance for the second quarter of the 2026 fiscal year. Reports figures such as revenue, operating income, ordinary income, and net income, with YoY comparisons. Segment details are unclear (some sections marked as unknown).
Read more -
Notice of Adoption of Business for the Social Impact Project in Fiscal Year 2026
Read more
Latest News (5 items)
Company Information
About
Cyfuse Biomedical K.K. develops, manufactures, and sells regenerative medicine-related products in Japan, Europe, and the United States. The company offers the Bio 3D Printer for use in the regeneration of various tissues and organs, such as cartilage and bone, blood vessels, and nerves; regenova, a 3D software that creates 3D data where spheroids shall be mounted; and S-PIKE that develops 3D-structures from cells. It also provides the Human 3D Mini-Liver, an in vitro MASH model that recapitulates human liver functions and predicts efficacy of drugs. Cyfuse Biomedical K.K. was incorporated in 2010 and is headquartered in Minato, Japan.
